Table 5. Multivariate analysis for overall survival and progression-free survival.
| Parameters | Overall survival | Progression-free survival | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | p-value | Hazard ratio (95% CI) | p-value | |
| Variables adjusted for age and sex | ||||
| RUNX3−/SMAD4+ vs. others* | 1.842 (1.079–3.143) | 0.025 | 1.850 (1.100–3.113) | 0.020 |
| Histologic grade | 1.517 (0.961–2.393) | 0.073 | 1.163 (0.730–1.852) | 0.525 |
| Tumor size | ||||
| ≤ 2 cm | 1 | Reference | 1 | Reference |
| > 2 cm and ≤ 4 cm | 1.511 (0.912–2.503) | 0.109 | 1.298 (0.787–2.142) | 0.307 |
| > 4 cm | 2.251 (1.287–3.935) | 0.004 | 2.191 (1.248–3.847) | 0.006 |
| Lymphatic invasion | 1.330 (0.962–1.839) | 0.085 | 1.492 (1.101–2.023) | 0.010 |
| Venous invasion | 1.547 (1.100–2.176) | 0.012 | 1.267 (0.896–1.792) | 0.180 |
| Perineural invasion | 1.546 (0.935–2.557) | 0.089 | 1.565 (0.982–2.494) | 0.059 |
| pT stage (7th Ed.) | 8.008 (1.071–59.866) | 0.043 | 10.211 (1.380–75.567) | 0.023 |
| pN stage (7th Ed.) | 1.178 (0.837–1.658) | 0.348 | 1.057 (0.758–1.474) | 0.745 |
*RUNX3-/SMAD4-, RUNX3+/SMAD4-, RUNX3+/SMAD4+.